By
Gabriel V. Rauterberg
affiliation not provided
Andrew Verstein
Yale Law School Center for the Study of Corporate Law
Abstract:
Financial indices, like the S&P 500 or the Consumer Price Index, have become a ubiquitous feature of our financial markets. One index, the London InterBank Offered Rate (“Libor”), may be the world’s most important number, an interest rate benchmark upon which hundreds of trillions of dollars depend. Yet, almost everyday new revelations emerge that Libor was tampered with during the height of the financial crisis by one or many of the world’s most prominent banks, with billions of dollars potentially misappropriated. This index disruption has attracted tremendous interest from regulators, private litigants, and market observers. Despite their importance, however, financial indices are poorly understood, and almost completely unstudied. In this Article, we explain why and how people use financial indices as well as how they are created. We show human discretion and value judgment to be essential ingredients in even the most “objective” indices. We then develop a taxonomy of financial indices, illustrating how the risks indices can pose, and the solutions applicable to those risks are intimately related to the motivation that drives the index’s creation. We show that the manipulation of indices is unsurprising given the precarious state of intellectual property rights in indices. While many call for prosecuting or regulating the Libor banks, our novel solution is to strengthen property rights for those who create financial indices.
Number of Pages in PDF File: 75
Keywords: Index, Indices, Libor, Swap, Derivative, Manipulation, Underproduction, Malproduction, Hot News, London InterBank Offered Rate, Finance, Syndicated Lending, CPI, S&P 500
Accepted Paper Series
Download the paper here.
Featured News
Google Heads to Court in Major DOJ Antitrust Battle Over Ad Practices
Sep 4, 2024 by
CPI
Starlink Yields to Brazil’s Supreme Court, Blocks X as Legal Battle Intensifies
Sep 4, 2024 by
CPI
Vestager Responds to EU Court Ruling on Illumina-Grail Merger
Sep 3, 2024 by
CPI
Generics and Biosimilars: The Missing Piece in US Drug Price Negotiations
Sep 3, 2024 by
CPI
Greek Regulator Investigates Novartis for Alleged Unfair Practices
Sep 3, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Canada & Mexico
Sep 3, 2024 by
CPI
Competitive Convergence: Mexico’s 30-Year Quest for Antitrust Parity with its Northern Neighbor
Sep 3, 2024 by
CPI
Competition and Digital Markets in North America: A Comparative Study of Antitrust Investigations in Mexico and the United States
Sep 3, 2024 by
CPI
Recent Antitrust Development in Mexico: COFECE’s Preliminary Report on Amazon and Mercado Libre
Sep 3, 2024 by
CPI
The Cost of Making COFECE Disappear
Sep 3, 2024 by
CPI